• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Alimera surges on buyout rumors

December 17, 2015 By Brad Perriello

Alimera(Reuters) — Alimera Sciences (NSDQ:ALIM), an ophthalmic pharmaceutical company, is in the early stages of exploring strategic alternatives, including a potential sale, according to people familiar with the matter.

The company has reached out to investment banks to seek advice on how it would be valued in a potential sale and who the likely buyers would be, the sources said this week, asking not to be identified because the deliberations are confidential.

Alpharetta, Ga.-based Alimera, which has a market value of around $100 million, did not respond to requests for comment.

A sale process would mark the culmination of a challenging year for Alimera. Its stock price has declined by more than ½ in 2015, in part reflecting difficulties persuading physicians to adopt 1 of its flagships, the Iluvien diabetic macular degeneration drug/device treatment co-developed with pSivida (NSDQ:PSDV).

After 3 rejections, the FDA in September 2014 approved Iluvien.

ALIM shares were trading at $3.02 apiece in mid-afternoon activity today, up 28.0%; PSDV shares were up 2.4% to $3.87.

Filed Under: Drug-Device Combinations Tagged With: Alimera Sciences, pSivida Corp.

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS